NCT06740370 2025-08-14
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
Sun Yat-sen University
Phase NA Recruiting
Clinical Trials
7 trialsNCT06622031 2025-01-13
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
Sun Yat-sen University
Phase NA Recruiting
NCT05215665 2024-12-11
GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase NA Recruiting
NCT06061276 2024-09-23
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
Sun Yat-sen University
Phase NA Recruiting
NCT06070636 2024-08-09
bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma
Sun Yat-sen University
Phase NA Recruiting
NCT06277024 2024-02-26
A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
Fujian Medical University
Phase NA Recruiting
NCT05444478 2023-11-07
Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
Sun Yat-sen University
Phase NA Recruiting